Skip to main content
Premium Trial:

Request an Annual Quote

CytRx's RXi Business Exclusively Licenses Invitrogen's RNAi IP for Rx Apps

NEW YORK (GenomeWeb News) — CytRx subsidiary RXi Pharmaceuticals will exclusively license Invitrogen’s second-generation RNAi technology for “designated target genes in all human therapeutic categories,” the companies said today.
The intellectual property covers Invitrogen’s Stealth technology and other tools related to chemically modified double-stranded RNA.
RXi CEO Tod Woolf said in a statement that the deal is “part of our strategy to enhance our proprietary rxRNA compounds for therapeutic applications.”
CytRx currently owns three clinical-stage compounds that use its small-molecule “molecular chaperone” co-induction technology, including candidates to treat amyotrophic lateral sclerosis, diabetic foot ulcers, and stroke recovery.
Invitrogen’s Stealth RNAi synthetic duplexes are used for RNAi research across both in vitro and in vivo applications, Amy Butler, Invitrogen vice president of gene-expression profiling, said in a statement.
She said the company sees the use of the technology in therapeutics as “a natural next step in Invitrogen’s efforts to be at the cutting edge of in vivo gene regulation.”

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.